Teriparatide

CAS No.: 52232-67-4

Atosiban Chemical Structure

Molecular formula:C₁₈₁H₂₉₁N₅₅O₅₁S₂

Molecular weight: 4117.77 g·mol⁻¹

Patent period: —

Dositive specifications:–

Injection :–

Oral tablets: —

Injection: —

Biological Activity

Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis;for the increase of bone mass in men with primary or hypogonadal osteoporosis;and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.

Chemical Properties

CAS NO.	52232-67-4
FORMULA	C₁₈₁H₂₉₁N₅₅O₅₁S₂
M.WT	4117.77 g·mol−1
Bioavailability	95%
Metabolism	Liver (nonspecific proteolysis)
STORAGE	-

Online Inquiry

Osteoporosis

Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures).

Other Drug Peptide

Terzapitide NEW

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide NEW

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Retatrutide NEW

Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.

Cagrilintide NEW

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.

Linaclotide NEW

Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.

BESTBELL